Evidence map›Paper›PMID 40637005›Full record

ArticleAmerican journal of medical genetics. Part A2025

First Report of BAP1-Associated Polyposis.

Angela L Jacobson, Maegan E Roberts, Lindsey Byrne, Jenna Wolfe, Peter P Stanich, Mohamed H Abdel-Rahman, Colin C Pritchard, Eric Q Konnick

Abstract readCase Reports
In one paragraph

Article in American journal of medical genetics. Part A, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Angela L JacobsonDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-6565-1459
Maegan E RobertsDivision of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.ORCID 0000-0002-0292-2557
Lindsey ByrneDivision of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.ORCID 0000-0001-7131-5331
Jenna WolfeDivision of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Peter P StanichDivision of Gastroenterology, Hepatology & Nutrition, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Mohamed H Abdel-RahmanDepartment of Ophthalmology and Visual Science, Havener Eye Institute, The Ohio State University, Columbus, Ohio, USA.ORCID 0000-0002-9493-7894
Colin C PritchardDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Eric Q KonnickDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
Spectrum of clinical phenotype of the BAP1-tumor predisposition syndrome (BAP1-TPDS)R01CA255323 · NCI · OHIO STATE UNIVERSITY · PI ABDEL-RAHMAN, MOHAMED H. · 2021 to 2025
$2.9M
NCI NIH HHS P50 CA097186NCI NIH HHS R01 CA255323NCI NIH HHS R01CA255323-01NIH SPORE CA097186
6 · The paper itself

Abstract

BAP1 Tumor Predisposition Syndrome (BAP1-TPDS) is caused by germline pathogenic variants in the BAP1 gene and has been associated with uveal melanoma, mesothelioma, cutaneous melanoma, renal cell carcinoma, and other benign cutaneous lesions. Adenomatous colon polyposis has not previously been reported as part of BAP1-TPDS. We report two patients with unexplained adenomatous oligopolyposis and germline BAP1 pathogenic variants. To determine if BAP1 had a role in polypogenesis, we performed somatic mutational analysis on multiple polyps from both patients (n = 8 total polyps tested). In every polyp tested, we found evidence of second BAP1 allele inactivation, including second somatic BAP1 mutations. Further, we did not detect any mutations in the commonly identified adenomatous polyposis pathway drivers, APC, CTNNB1, or other WNT/β-catenin. We did not detect somatic BAP1 mutations in any adenomatous polyps from patients without germline BAP1 pathogenic variants (n = 151 patients), highlighting the specificity of somatic BAP1 second hit mutations in BAP1 germline carrier polyps. Our findings strongly support that the polyps in these patients were caused by BAP1, and that adenomatous oligopolyposis is a part of the BAP1-TPDS tumor spectrum. Further work is needed to characterize the penetrance of this new BAP1-associated phenotype.

Indexed as

Adenomatous Polyposis ColiGenetic Predisposition to DiseaseTumor Suppressor ProteinsUbiquitin ThiolesteraseAdultDNA Mutational AnalysisFemaleGerm-Line MutationHumansMaleMiddle AgedMutationBAP1 protein, humanTumor Suppressor ProteinsUbiquitin Thiolesteraseadenomasadenomatous polyposisBAP1BAP1‐TPDSgermlinepolyps

Identifiers

PMID40637005
PMCPMC12851413

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.